Phase II Trial Of Neoadjuvant Concurrent Capecitabine, RHUMAB VEGF (Avastin) And Radiotherapy In Patients Presenting With Locally Advanced Rectal Cancer

Trial Profile

Phase II Trial Of Neoadjuvant Concurrent Capecitabine, RHUMAB VEGF (Avastin) And Radiotherapy In Patients Presenting With Locally Advanced Rectal Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Bevacizumab; Capecitabine
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Nov 2009 Actual end date (Jan 2009) and actual number of patients (25) added as reported by ClinicalTrials.gov.
    • 12 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 06 Nov 2008 Planned end date changed from 1 Feb 2008 to 1 Dec 2008, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top